Eikon Therapeutics

Eikon Therapeutics seeks to advance breakthrough therapeutics through the purposeful integration of engineering and science. The company discovers and develops new medicines by inventing new technologies to provide quantitative information about the behavior of biological systems. Eikon’s proprietary single-molecule tracking (SMT) platform can visualize hundreds of thousands of protein motion events in living cells in less than a second, enabling precise measurement of the dynamic behavior of individual protein molecules on a massive scale. The company has clinical programs that have shown evidence of activity in the treatment of solid tumors and is advancing numerous preclinical programs across a broad range of therapeutic areas, including oncology, immunology, and neuroscience. Eikon leverages traditional high-performance tools and builds new instruments when needed to explore cell and molecular biology in innovative ways. The company integrates AI capabilities and advanced automation with its SMT platform to inventory molecular interactions with extraordinary scale and precision. Additionally, Eikon uses Nobel Prize-winning super-resolution fluorescence microscopy tools to visualize the dynamics of macromolecules within live cells. With a growing therapeutic pipeline, Eikon aims to deliver important new medicines to address serious illnesses with severely unmet medical needs. The company has locations at 3929 Point Eden Way, Hayward, CA 94545; 450 East 29th St @ 1st Ave, 15th Floor, New York, NY 10016; 24590 Clawiter Road, Hayward, CA 94545; and 3 2nd St, 4th Floor, Jersey City, NJ 07302.